trending Market Intelligence /marketintelligence/en/news-insights/trending/v-1bctokcg-gsat8lwma0q2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Helix BioPharma, ProMab to collaborate on cell-based therapies

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


Helix BioPharma, ProMab to collaborate on cell-based therapies

Helix Biopharma Corp. will collaborate with ProMab Biotechnologies Inc. to develop cell-based therapies.

Under a nonbinding letter of intent, the companies will complete a due diligence and establish a collaboration to develop chimeric antigen receptor T cell therapy for hematological malignancies and solid tumors.